New study presented at the 2026 ASCO Annual Meeting suggest GLP-1 weight-loss drugs such as Ozempic may offer significant cancer benefits. Researchers found a 30% reduction in breast cancer risk, a 30% drop in breast cancer deaths when combined with treatment, and up to a 50% lower risk of cancer spread across multiple cancers.